Screener
Zymeworks ZYME ZW191 — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Zymeworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001937653-26-000047
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Zanidatamab | $2,181 | $1,501 | $2,805 | $2,905 |
| ZW171 | (458) | 3,322 | 691 | 5,549 |
| ZW191 | 3,127 | 2,764 | 6,158 | 4,470 |
| ZW220 | (152) | 327 | (55) | 2,525 |
| ZW251 | 3,205 | 2,340 | 5,112 | 6,291 |
| Expense for other preclinical and research programs | 4,192 | 6,174 | 11,456 | 12,250 |
| Unallocated research and development expenses: | ||||
| Salaries and benefits and stock based compensation | 10,681 | 12,034 | 25,440 | 24,757 |
Item 1. Financial Statements
FAQ
- What is Zymeworks's ZW191 — R&D?
- Zymeworks (ZYME) reported ZW191 — R&D of $3.13M in Q2 2026.
- What does ZW191 — R&D mean?
- This metric represents the total investment allocated to the research and development activities specifically associated with the ZW191 clinical candidate. It captures the resources dedicated to advancing this specific therapeutic asset through its various stages of discovery and clinical evaluation. Tracking this investment helps stakeholders assess the company's commitment to prioritizing this asset within its broader biopharmaceutical pipeline.
Ask your AI about Zymeworks's zw191 — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude